tiprankstipranks
Trending News
More News >

Everest Medicines Expands NEFECON’s Reach in Asia

Everest Medicines Expands NEFECON’s Reach in Asia

Everest Medicines Ltd. (HK:1952) has released an update.

Confident Investing Starts Here:

Everest Medicines has announced the approval of its kidney disease drug NEFECON by the Taiwan Food and Drug Administration, marking a significant expansion in its treatment reach for IgA nephropathy, particularly in Asia where the condition is more prevalent. The company also highlighted promising results from a two-year clinical trial in China, showing substantial kidney function protection and reduction in proteinuria among patients. With approvals across several Asian regions, NEFECON is poised to become a leading treatment option for IgAN patients.

For further insights into HK:1952 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1